- Home
- GNLX vs RZLT Comparison
GNLX vs RZLT Comparison
Compare GNLX & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- RZLT
- Stock Information
- Founded
- GNLX 2001
- RZLT 2010
- Country
- GNLX United States
- RZLT United States
- Employees
- GNLX N/A
- RZLT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- RZLT Health Care
- Exchange
- GNLX Nasdaq
- RZLT Nasdaq
- Market Cap
- GNLX 128.0M
- RZLT 626.4M
- IPO Year
- GNLX 2023
- RZLT N/A
- Fundamental
- Price
- GNLX $3.91
- RZLT $7.71
- Analyst Decision
- GNLX Strong Buy
- RZLT Strong Buy
- Analyst Count
- GNLX 4
- RZLT 4
- Target Price
- GNLX $17.75
- RZLT $11.67
- AVG Volume (30 Days)
- GNLX 151.7K
- RZLT 921.0K
- Earning Date
- GNLX 11-13-2025
- RZLT 11-06-2025
- Dividend Yield
- GNLX N/A
- RZLT N/A
- EPS Growth
- GNLX N/A
- RZLT N/A
- EPS
- GNLX N/A
- RZLT N/A
- Revenue
- GNLX N/A
- RZLT N/A
- Revenue This Year
- GNLX N/A
- RZLT N/A
- Revenue Next Year
- GNLX N/A
- RZLT N/A
- P/E Ratio
- GNLX N/A
- RZLT N/A
- Revenue Growth
- GNLX N/A
- RZLT N/A
- 52 Week Low
- GNLX $1.95
- RZLT $2.22
- 52 Week High
- GNLX $5.89
- RZLT $8.34
- Technical
- Relative Strength Index (RSI)
- GNLX 59.55
- RZLT 64.10
- Support Level
- GNLX $3.76
- RZLT $7.23
- Resistance Level
- GNLX $3.61
- RZLT $8.34
- Average True Range (ATR)
- GNLX 0.25
- RZLT 0.36
- MACD
- GNLX 0.05
- RZLT -0.05
- Stochastic Oscillator
- GNLX 67.03
- RZLT 55.83
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.